ArticleInternational journal of nanomedicine2017
Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis.
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Meta-Analysis of Drug Delivery Approaches for Treating Intracellular Infections.Pharmaceutical research · 2022Pooled it
- StandardizedVeterinary sciences · 2025Article
- Plant-derived products as anti-leishmanials which target mitochondria: a review.Expert reviews in molecular medicine · 2025Review
- Synergistic Effects of Artesunate in Combination with Amphotericin B and Miltefosine againstAntibiotics (Basel, Switzerland) · 2024Article
- Development and characterization of liposomal formulations containing sesquiterpene lactones for the treatment of chronic gout.Scientific reports · 2024Article
- A novel outlook in the delivery of artemisinin: production and efficacy in experimental visceral leishmaniasis.Pathogens and global health · 2024Article
- The Prospects of Phytomedicines and Nanomedicines to Treat Leishmaniasis: A Comprehensive Review.Current drug research reviews · 2024Review
- Curcumin-loaded nanostructured systems for treatment of leishmaniasis: a review.Beilstein journal of nanotechnology · 2024Review
- Applicability of Redirecting Artemisinins for New Targets.Global challenges (Hoboken, NJ) · 2023Review
- Article
- Novel Transethosomal Gel Containing Miconazole Nitrate; Development, Characterization, and Enhanced Antifungal Activity.Pharmaceutics · 2023Article
- Liposomal drug delivery systems for the treatment of leishmaniasis.Parasitology research · 2022Review
- Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products.Frontiers in chemistry · 2022Review
- Artemether-loaded nanostructured lipid carriers: preparation, characterization, and evaluation ofResearch in pharmaceutical sciences · 2021Article
- An Overview on the Therapeutics of Neglected Infectious Diseases-Leishmaniasis and Chagas Diseases.Frontiers in chemistry · 2021Review
- Critical Antileishmanial in vitro Effects of Highly Examined Gold Nanoparticles.International journal of nanomedicine · 2021Article
- Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis.Parasitology research · 2021Article
- Potential of Artesunate in the treatment of visceral leishmaniasis in dogs naturally infected by Leishmania infantum: Efficacy evidence from a randomized field trial.PLoS neglected tropical diseases · 2020Article
- Article
- Evaluation of the Pharmacophoric Role of the O-O Bond in Synthetic Antileishmanial Compounds: Comparison between 1,2-Dioxanes and Tetrahydropyrans.Journal of medicinal chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral leishmaniasis (VL) is a fatal, vector-borne disease caused by the intracellular protozoa of the genus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.